Chemotherapy drugs are essential in cancer treatment, targeting rapidly dividing cells to prevent tumor growth and proliferation. Understanding their mechanisms of action helps optimize their use in clinical practice, improving patient outcomes while managing side effects.

Alkylating Agents and Platinum Analogs

Alkylating agents such as cyclophosphamide and melphalan, along with platinum analogs like cisplatin and carboplatin, work by creating cross-links within DNA strands. These cross-links prevent the DNA from unwinding and replicating, leading to cell death. Alkylating agents add alkyl groups to the DNA, causing breaks and mispairing, while platinum compounds form covalent bonds with DNA, creating intrastrand and interstrand cross-links that hinder DNA repair and replication​ (Frontiers)​​ (OncLive)​.

Antimetabolites

Antimetabolites disrupt DNA and RNA synthesis by mimicking the natural substrates of these molecules. Drugs such as methotrexate, 5-fluorouracil (5-FU), and cytarabine are incorporated into DNA or RNA during the synthesis phase. Methotrexate inhibits dihydrofolate reductase, reducing the availability of thymidylate and purines necessary for DNA synthesis. 5-FU interferes with thymidylate synthase, disrupting the synthesis of thymidine, a crucial DNA building block. These disruptions lead to faulty DNA replication and cell death​ (Frontiers)​​ (OncLive)​.

Topoisomerase Inhibitors

Topoisomerase inhibitors like doxorubicin and etoposide target the enzymes topoisomerase I and II, which are essential for DNA replication and transcription. These drugs stabilize the transient breaks that topoisomerases introduce into the DNA to relieve torsional strain during replication. By preventing the re-ligation of these breaks, topoisomerase inhibitors cause DNA damage and cell death. Doxorubicin intercalates into DNA, interfering with topoisomerase II and generating free radicals that further damage cellular components​ (Frontiers)​​ (OncLive)​.

Microtubule Inhibitors

Microtubule inhibitors such as paclitaxel (Taxol) and vincristine disrupt the mitotic spindle, which is crucial for cell division. Paclitaxel stabilizes microtubules, preventing their disassembly, which halts the cell cycle in the mitotic phase and leads to apoptosis. Conversely, vincristine binds to tubulin and inhibits microtubule formation, also preventing mitosis. Both mechanisms result in the failure of cancer cells to divide properly, leading to cell death​ (Frontiers)​​ (OncLive)​.

Novel Mechanisms and Future Directions

Antibody-drug conjugates (ADCs) represent a novel approach combining chemotherapy with targeted therapy. ADCs link cytotoxic drugs to monoclonal antibodies that specifically target cancer cell antigens. For example, brentuximab vedotin targets CD30 on lymphoma cells, delivering the cytotoxic agent directly to the cancer cells, minimizing damage to healthy tissues. This targeted delivery enhances the efficacy of chemotherapy while reducing systemic toxicity​ (OncLive)​.

Immunogenic cell death (ICD) is another emerging mechanism, particularly with platinum-based drugs like oxaliplatin. ICD stimulates the immune system to recognize and attack cancer cells. By promoting an immune response, these drugs not only kill cancer cells directly but also help the body mount a long-term defense against tumor recurrence​ (Frontiers)​​ (OncLive)​.

The diverse mechanisms through which chemotherapy drugs act—ranging from DNA damage to microtubule disruption and targeted delivery systems—highlight the complexity and sophistication of modern cancer treatment. Continuous research and development in this field promise to further enhance the effectiveness of chemotherapy, offering hope for better patient outcomes with fewer side effects.


References

  1. Frontiers in Oncology. “Cancer Chemotherapy: Insights into Cellular and Tumor Microenvironmental Mechanisms of Action.” 2024.
  2. OncLive. “Mechanisms of Action of Antibody-Drug Conjugates.” 2024.
  3. ScienceDirect. “Principles of Cancer Treatment by Chemotherapy.” 2024.

Photo:Dreamstime